Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 76Neoplasm Metastasis 13Stomach Neoplasms 12Neoplasms 8Breast Neoplasms, Male 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Endometrial Neoplasms 6Esophageal Neoplasms 5Colorectal Neoplasms 5Brain Neoplasms 5Ovarian Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Testicular Neoplasms 2Somatostatinoma 2Solid Tumor 2

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × Trastuzumab × Clear all
NCT01351350 2019-08-08

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Takeda

Phase 1 Completed
68 enrolled 29 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡